Back to Stakeholders

Research with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.

Academic Research

1 papers

Published Papers

1

Trial Involvement

5

Distinct Focus Topics

0

Latest Publication

Feb 13, 2026

Research journey

Columbia University works on Psilocybin. Here is where that compound’s research stands.

Research journey

332 trials · 753 papers

Full timeline →

Tap any milestone for detail. 1958 to 2026.

Quick Facts

Type
academic
HQ
United States
Website
Visit

Research Landscape

What the 5 registered trials Columbia University sponsors or participates in look like when you line them up. Counts come from Blossom’s trial records as of July 2026.

What's live right now, and what stopped?

Sourced

Registry status of all 5 Columbia University trials Blossom tracks. Orange marks trials recruiting or opening.

Recruiting or opening
360%
Completed
120%
Stopped early
120%
Browse trials →

Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.

Sponsored Trials

2
TerminatedI

The Role of HNKs in the Antidepressant Effect of Ketamine

Start Date
Compounds
Ketamine
CompletedII

Ketamine in the Treatment of Depression

Start Date
Compounds
Ketamine, Placebo

Collaborated Trials

3
Not yet recruitingII

Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence (PsiPTSD)

Start Date
Compounds
Psilocybin
Not yet recruitingII

PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study (PATSUD)

Start Date
Compounds
Psilocybin
RecruitingI

Treatment of Persistent Post-concussive Symptoms With Psilocybin Assisted Therapy (PatACT)

Start Date
Compounds
Psilocybin

Research Papers

1
Paywallmeta

Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones

This pooled analysis (s=9) examined how much session facilitators shape participants' acute subjective effects across psilocybin studies involving 298 participants and 60 facilitators, finding that facilitator influence was negligible in healthy volunteers (0.8% of variance) but clinically meaningful in patient samples (13.6%), comparable to or exceeding typical therapist effects seen in conventional psychotherapy.

Published
Journal
Psychiatry Research
Authors
Goldy, S. P., Sepeda, N. D., Hilbert, S. N., Bari, B. A., Garcia-Romeu, A., Gukasyan, N., Barrett, F. S., Yaden, D. B., Nayak, S. M.